Objective-Currently prescribed antiplatelet drugs have 1 common side effect-an increased risk of hemorrhage and thrombocytopenia. On the contrary, bleeding defects associated with glycoprotein VI (GPVI) expression deficiency are usually slightly prolonged bleeding times. However, GPVI antagonists are lacking in clinic. Approach and Results-Using reverse-phase high-performance liquid chromatography and sequencing, we revealed the partial sequence of trowaglerix α subunit, a potent specific GPVI-targeting snaclec (snake venom C-type lectin protein). Hexapeptide (Troα6 [trowaglerix a chain hexapeptide, CKWMNV]) and decapeptide (Troα10) derived from trowaglerix specifically inhibited collagen-induced platelet aggregation through blocking platelet GPVI receptor. Computational peptide design helped to design a series of Troα6/Troα10 peptides. Protein docking studies on these decapeptides and GPVI suggest that Troα10 was bound at the lower surface of D1 domain and outer surface of D2 domain, which was at the different place of the collagen-binding site and the scFv (single-chain variable fragment) D2-binding site. The newly discovered site was confirmed by inhibitory effects of polyclonal antibodies on collagen-induced platelet aggregation. This indicates that D2 domain of GPVI is a novel and important binding epitope on GPVI-mediated platelet aggregation. Troα6/Troα10 displayed prominent inhibitory effect of thrombus formation in fluorescein sodium-induced platelet thrombus formation of mesenteric venules and ferric chloride-induced carotid artery injury thrombosis model without prolonging the in vivo bleeding time. Conclusions-We develop a novel antithrombotic peptides derived from trowaglerix that acts through GPVI antagonism with greater safety-no severe bleeding. The binding epitope of polypeptides on GPVI is novel and important. These hexa/ decapeptides have therapeutic potential for developing ideal small-mass GPVI antagonists for arterial thrombogenic diseases. Visual Overview-An online visual overview is available for this article. GPVI and GPIb. 10, 11 The structure of GPVI together with its ligand has been partially determined, 12 casting some light on the potential binding sites at molecular level. Because GPVI ligand complex structure was not fully evaluated, the detailed GPVI-ligandbinding domain and the dissection of critical sequence responsible for design of target inhibition still need further investigation.
P latelets play a pivotal role in thromboembolic diseases and participate in early stages of the pathophysiological process. Therefore, antiplatelet drugs have become a major class of therapeutics used to prevent and reverse platelet aggregation in acute coronary diseases, the leading cause of death in the world. 1, 2 Currently prescribed antiplatelet drugs, including cyclooxygenase inhibitors, phosphodiesterase inhibitors, ADP receptor antagonists, and glycoprotein (GP) IIb/IIIa receptor antagonists, have 1 common side effect-an increased risk of hemorrhage and thrombocytopenia. 3, 4 Thus, the ideal efficacious antithrombotic agents with minimal bleeding side effect are under active investigation. Experimental and clinical evidence has shown that platelets deficient in GPVI fail to activate/aggregate in response to collagen, but this deficiency in GPVI expression does not lead to severe bleeding. 5, 6 As a result, GPVI has emerged as a potential pharmacological target because the inhibition of this receptor seems to ideally exhibit antithrombotic efficacy with good safety.
See accompanying editorial on page 1266
Snake venoms contain many biological components that affect hemostasis by disrupting endothelium or affecting coagulation factors and ultimately affecting platelet functions. Specifically, snaclecs (snake venom C-type lectin protein) 7 composed of αβ heterodimers are often oligomerized to form large molecules and interact with specific platelet receptors, such as GPIb, α2β1, or GPVI receptors, to activate or inhibit platelet function. 8, 9 CVX (convulxin), a multimeric protein derived from Crotalus durissus terrificus venom, is the first identified snaclec capable of inducing platelet activation via binding to GPVI and GPIb. 10, 11 The structure of GPVI together with its ligand has been partially determined, 12 casting some light on the potential binding sites at molecular level. Because GPVI ligand complex structure was not fully evaluated, the detailed GPVI-ligandbinding domain and the dissection of critical sequence responsible for design of target inhibition still need further investigation.
Previous literature has shown that GPVI recognizes glycine-proline-hydroxyproline repeat motifs in the triple helical structure of collagen. 13 GPVI has 2 extracellular C2-type immunoglobulin-like domains (D1 and D2). The residues of GPVI extracellular domain, involved in the GPVI-collagen interaction, are majorly located on the surface of D1 domain. 14, 15 It also was suggested that CVX exists in solution as a dimer of α4β4 rings and contains 8 distinct GPVI-binding sites and binds GPVI with high-binding affinities. 16 Also, presence of 2 distinct GPVI-binding surfaces on the (α4β4)2 CVX dimers allows CVX to both cluster GPVI on a single cell and to cross-link target cells via GPVI.
We previously demonstrated that Trowaglerix, a novel snaclec purified from Tropidolaemus wagleri venom, specifically activated platelets via GPVI when compared with CVX (mixed binding of GPVI and GPIb). 17 Here, we determined the partial amino acid sequences of trowaglerix and synthesized the small-mass peptides derived from these snaclecs C terminal accordingly. We found that the hexa-/decapeptides of trowaglerix α subunit specifically exhibited marked inhibitory activity on collagen-induced platelet aggregation by interacting with GPVI receptor in vitro and effectively exerted antithrombotic activity in mice model without causing bleeding tendency. Through computational peptide design and molecular dynamic simulations on the decapeptides and GPVI, the possible binding site was identified near D1/D2 domain surface, which is different from well-known collagen-binding site.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Hexapeptide and Decapeptide Derived From Trowaglerix Specifically Inhibit Collagen-Induced Platelet Aggregation and Downstream Activation Cascade
Trowaglerix α subunit obtained from reverse-phase high-performance liquid chromatography ( Figure 1A ) was more effective in inhibiting collagen-induced platelet aggregation compared with β subunit ( Figure 1B) . The sequences are similar to several other snaclecs with some distinctive differences observed ( Figure 1C ).
Several hexapeptides from snaclecs of C terminus, including CVX (CVXα6/CVXβ6), trowaglerix (Troα6 [trowaglerix a chain hexapeptide, CKWMNV]), aggretin (also called rhodocytin, a α2β1/CLEC-2 agonist, Aggα6/Aggβ6), and agkistin (a GPIb agonist, Agkα6/Agkβ6), were used to investigate their effects on collagen-induced platelet aggregation. As shown in Figure 2A , trowaglerix hexapeptide (Troα6 100 μg/mL, 128.2 μmol/L) showed the most potent inhibitory effect (almost 50% inhibition) on collagen-induced aggregation. Thus, Troα6 was selected for further mutation studies to investigate which amino acid is critical for its inhibitory activity. The inhibitory activity of Troα6 was diminished by mutating the specific amino acid residue (W116A; Figure 2B ), indicating that this tryptophan residue is critical for the expression of Troα6 inhibitory activity. Moreover, scrambled peptide(s) showed little effect.
As shown in Figure 2C , Troα6 specifically inhibited collagen-induced platelet aggregation in platelet suspension and human platelet-rich plasma without affecting platelet aggregation stimulated by other agonists (ADP, thrombin, ristocetin, or gramicetin). Therefore, Troα6 was proposed to specifically interact with collagen receptors (integrin α2β1 or GPVI) to inhibit collagen-induced platelet aggregation. Decapeptides were further investigated by extending the original hexapeptides (decapeptide, Troα10, and GFCKWMNVAC) to evaluate their effects on collagen-induced platelet aggregation. Troα10 displayed more prominent inhibitory effect on collagen-induced platelet aggregation than Troα6 at the same concentration (100 μg/mL), with IC 50 (half maximal inhibitory concentration) of 30.42±9.52 and 106.90±11.09 μmol/L, respectively ( Figure 2D ). Troα6/Troα10 also displayed concentrationdependently inhibitory effects on P-selectin expression, thromboxane A 2 formation, and intracellular calcium concentration In addition, the inhibitory activity of Troα10 was diminished by the substitution of 5 amino acid residues, including a glycine residue (Gly, G), a phenylalanine (Phe, F) residue, 2 sites of half-cystine (Cys, C), and a tryptophan (Trp, W) residue ( Figure 2E ), indicating that these residues are essential for maintaining the activity of Troα10.
Troα6/Troα10 Binds To Platelet GPVI and Inhibits GPVI Signal Transduction in Platelets Activated by Collagen
We used flow cytometry to elucidate the binding site of Troα6/ Troα10 on human platelets. As shown in Figure 3A , FITC (fluorescein isothiocyanate)-conjugated Troα10 concentration dependently bound to platelets and almost saturated at a concentration of 300 μg/mL (FITC-conjugated Troα6 showed the similar effect in Figure ID in the online-only Data Supplement). To further confirm the GPVI-Troα10 interaction, an ELISA was performed. Biotin-conjugated Troα10 binds to recombinant GPVI in a concentration-dependent manner as shown in Figure 3B . It also reveals a high-affinity binding of Troα10 (apparent dissociation constant Kd=9.06±2.59 µg/ mL [7.82±2.24 μmol/L]). A major 60-kDa platelet membrane protein was specifically recognized by a GPVI mAb, 326E12 ( Figure 3C) . Synthetic Troα10 was also tested for its inhibitory effect on GPVI binding to collagen in ELISA experiment.
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Troα10 showed essentially no inhibitory effect on GPVI binding to collagen even at high concentrations ( Figure 3D ), indicating that the binding epitope of Troα10 on GPVI may be different from those of 326E12 and collagen. Furthermore, to confirm GPVI as the major target for Troα10-mediated platelet-collagen association, we also compared the concentration-inhibition curves by collagen and CVX ( Figure 3E ). Troα10 also has the ability to inhibit CVX-induced platelet aggregation in platelet suspension with similar inhibition pattern when compared to collagen. The binding of collagen to platelet GPVI receptor is known to trigger platelet aggregation through sequential tyrosine phosphorylation of signaling molecules. 18 In the presence of decapeptide, collagen-induced tyrosine phosphorylation of these kinases (including Src, Fyn, LAT, and PLCγ2 [phospholipase Cγ2]) and the subsequent platelet activation were suppressed ( Figure IE in the online-only Data Supplement).
The Possible GPVI Binding Sites of the Decamer Was Located at the Inner Surface Between the D1 and D2 Domains
To understand the potential binding sites of the trowaglerix peptides at GPVI, exhaustive docking of the trowaglerix decamer peptide with the entire surface of GPVI was performed. First, the 3-dimensional structure of the decamer peptide from trowaglerix was predicted ( Figure 4A ). The residues from 3Cys to 6Met formed an α helix, as other residues formed a linear-like structure. The decamer peptide was folded in a U-shaped form.
Unlike the entire C-type lectin-like snake venom proteins which contain GPVI-binding sites at the boundary between the α and β subunits of the proteins, the docking models showed that the binding site of trowaglerix α decamer was at the inner surface of the area between D1 and D2 domains of GPVI ( Figure 4B ). From the docked position, residues 12 to 16 in D1 domain provided a cavity for fitting the lysine 4 of the peptide. Also, cysteine 10 of the peptide might have hydrogen bond interaction with the main chain oxygen atoms of the residues glycine 129 and asparagine 136 in D2 domain. We further designed polyclonal antibodies, one targeting the outer surface at D2 domain (D2[A]), and the other targeting collagen-binding site at D1 domain (D1[B]), which are the predicted epitopes toward Troα10, to investigate their effects on collagen-induced platelet aggregation. The D1 and D2 targeting epitopes were KEGDPAPYKNPER (D2[A]) and QGPPGVDLYRLEK (D1[B]). As shown in Figure 4C , antibodies against outer surface at D2 showed better inhibitory effects on collagen-induced platelet aggregation, compared with antibodies against collagen-binding site at D1 domain. Antibody against outer surface at D2 displayed more prominent inhibitory effect than antibody against collagen-binding site at D1, indicating that the predicted binding epitope of Troα10 on GPVI D2 domain is a novel binding candidate for developing anti-GPVI agents.
Antithrombotic Activity of Troα6/Troα10 in Ex Vivo and In Vivo Model
We next investigated the ex vivo antithrombotic effect of Troα6/Troα10 by examining the responsiveness of plateletrich plasma prepared from Troα6/Troα10-treated mice toward 
shown at the bottom (about 44%-46%). The sequences were obtained from the previous study. 18 The underlined sequence is for Troα6 (trowaglerix a chain hexapeptide, CKWMNV) and other synthetic hexapeptides.
collagen. Platelet aggregation response induced by collagen was significantly inhibited in platelet-rich plasma prepared from mice pretreated with Troα6 (30 mg/kg, % of inhibition: 57.07±6.06, n=22) or Troα10 (8 mg/kg, % of inhibition: 85.27±7.78, n=10) for 5 minutes ( Figure 5A ). However, the platelet counts, as measured at 5 minutes after the administration of Troα6/Troα10, were not altered.
Furthermore, the in vivo antithrombotic effect of Troα6 was examined by thrombus formation in irradiated mesenteric venules of mice pretreated with fluorescein sodium. As shown in Figure 5B , intravenous administration of Troα6 (30 mg/ kg) delayed thrombus formation and significantly prolonged the time to occlusion from 134.9±10.34 s (control, n=19) to 315.9±21.89 s (n=20). Initially, we chose Troα10 30 mg/ kg to perform in vivo study. However, we found that decapeptide exhibits more prominent inhibition than hexapeptide both in in vitro and ex vivo experiments ( Figures 2D and 5A) . Therefore, we used a lower dose of decapeptide to examine its effect. Troα10 (10 mg/kg) also markedly prolonged the occlusion time to 294.5±25.38 s (n=19). On the other hand, at the Figure 1C is for Troα6 (trowaglerix a chain hexapeptide, CKWMNV) and other synthetic hexapeptide, 100 μg/mL): convulxin α and β (CVXα6/CVXβ6), trowaglerix α (Troα6), aggretin α and β (Aggα6/Aggβ6), agkistin α and β (Agkα6/Agkβ6), at 37°C for 3 min. After incubation, platelets were stimulated with collagen (3 μg/mL) to trigger platelet aggregation. Results are expressed as percentage of inhibition. Data are presented as mean±SEM (n=3-4). B, Washed human platelets were preincubated with hexapeptide (Troα6), its mutants or scrambled hexapeptides (s, 100 μg/mL) at 37°C for 3 min, and then stimulated with collagen (3 μg/mL) to trigger platelet aggregation. Results are expressed as percentage of inhibition. Data are presented as mean±SEM (n=3-4). C, Human platelet-rich plasma (PRP) was preincubated (upper arrowhead) with hexapeptide (Troα6, 200 μg/mL) at 37°C for 3 min, and then stimulated (lower arrowhead) with collagen (2 μg/mL), or ADP (20 μmol/L) to trigger platelet aggregation. Washed human platelets (PS) were preincubated (upper arrowhead) with Troα6 (100 μg/mL) at 37°C for 3 min, and then stimulated (lower arrowhead) with collagen (3 μg/mL) or thrombin (0.05 U/mL) to trigger platelet aggregation, ristocetin (1 mg/mL) in the presence of small amount of plasma (10 μL) as the source of von Willebrand factor or gramicetin (1 μg/mL) to trigger platelet agglutination. This is representative of at least 3 similar results obtained from separate experiments. D, Washed human platelets were preincubated (upper arrowhead) with Troα6 or Troα10 at the same concentration (100 μg/mL) at 37°C for 3 min, and then stimulated (lower arrowhead) with collagen to trigger platelet aggregation. E, Washed human platelets were preincubated with Troα10 and its mutants (100 μg/mL) at 37°C for 3 min, and then stimulated with collagen (5 μg/mL) to trigger platelet aggregation. Results are expressed as percentage of inhibition. Data are presented as mean±SEM (n=3-4).
dose of 250 mg/kg, aspirin increased the occlusion time to 298.7±29.55 s (n=15). In FeCl3-induced arterial thrombosis model, complete carotid artery occlusion occurred in control ICR (imprinting control region) mice in response to 5% FeCl3 within 15 minutes, whereas Troα10 (8 mg/kg)-treated mice showed no appreciable changes in blood flow ≤60 minutes ( Figure 5C ). These data showed that intravenous administration of hexa-/decapeptide exhibited antithrombic activity both ex vivo and in vivo in mice.
The prolonged bleeding phenotype is the common undesirable side effect after antithrombotic therapy. A mouse tail transection model was used to examine the influence of hexa-/decapeptide on hemostasis in vivo. As shown in Figure 5D 
Discussion
In this study, we have identified the partial amino acid sequences of trowaglerix, a specific GPVI-binding snaclec α subunit. 17 We have also predicted the structure of decapeptide and analyzed its possible binding sites at the inner surface of the area between D1 and D2 domains of GPVI, which is novel and probably different from well-known collagen-binding site. Most importantly, we found that the hexa-/decapeptide of trowaglerix α subunit (Troα6/Troα10) specifically exhibited inhibitory activity toward collagen-induced aggregation via interacting with platelet GPVI receptor and displayed antithrombotic effect in vivo. To our knowledge, this is the first study to design small-mass peptides derived from snaclecs with antithrombotic activity that target platelet GPVI receptor with atypical binding epitope.
In this study, the inhibitory activity of Troα6 was diminished with mutant W116A but not mutant M117A (Figure 2B ), indicating that tryptophan is critical for the activity expression of Troα6. Alanine scanning of Troα10 in collagen-induced platelet aggregation experiment demonstrated that the Gly, 1 Phe, 2 Cys, 3 Trp, 5 and Cys 10 residues are important for the activity of Troα10 ( Figure 2E ). Structural modeling of snaclecs has been a fairly useful approach for establishing putative binding sites on their surfaces, based on the premise that interactions with ligands involve electrostatic, as well as shape-matching interactions. There are only a few laboratories that are conducting functional studies to prove the importance of these potential ligand-receptor-binding residues. This study is one of the pioneering functional studies to investigate the effect of snaclecs fragments and their mutants on platelet aggregation. We propose that Troα10 inhibits collagen-induced aggregation via interacting with GPVI by the following evidence: (1) Troα10 binds to immobilized GPVI in a concentrationdependent manner ( Figure 3B ) and (2) the eluted platelet membrane proteins bound to biotinylated Troα10 were recognized by anti-GPVI mAb ( Figure 3C ). Our docking result also showed that the possible GPVI-binding sites of decapeptide are located at the lower surface of D1 domain and outer surface of D2 domain ( Figure 4B ) and are different from that of 326E12 or collagen. The polyclonal antibodies against binding surface at the D2 domain showed inhibitory effects on collagen-induced platelet aggregation, indicating that surface at the D2 domain of GPVI is a novel and important binding epitope on GPVImediated platelet aggregation. We also compared the GPVI sequences at the Troα10-binding site between human and mouse. In the sequence of Troα10-binding site in the mouse GPVI, there are 4 different residues from human: GLN13 (LEU in human), ILE86 (VAL in human), ARG136 (ASN in human), and LYS139 (ARG in human). However, the decapeptide only interacts with LEU13 and ASN136 using hydrogen bonds with the carboxyl groups at the peptide main chain in human GPVI. At the residues 86 and 139, these amino acids differences are of similar amino acid types with positive charges (ARG and LYS). It is reasonable to assume similar interactions at potential binding sites of D1/D2 domain between human and mouse GPVI.
Our present results demonstrated that Troα6/Troα10 inhibited platelet responses to collagen ex vivo without causing thrombocytopenia and delayed the occlusion time of irradiation-induced thrombus formation in vivo, but did not prolong bleeding time ( Figure 5 ). Up to date, there are few smallmass GPVI inhibitors reported as efficacious antithrombotic, although many anti-GPVI antibodies and GPVI mimetics have been reported. Recently, a dimeric GPVI-Fc (fragment crystallizable) (Revacept), which can bind to collagen with high affinity, was classified as a GPVI mimic. 19 There are some differences between our decapeptide and Revacept as follows: (1) Revacept, a GPVI-mimicking fusion protein, competitively blocks the GPVI-binding site of collagen; Troα10, a small molecule GPVI-function blocking agent, binds to GPVI, interfering with collagen-GPVI interaction and (2) the administration route of Revacept is limited to injection, whereas Troα10 may be used orally after optimized transformation into nonpeptide mimetics. We provide a novel skeleton for developing specific small-mass antagonist of platelet GPVI for prevention of arterial thrombosis. We are now developing an in silico peptide design by Greedy approach 20 with system mutation inspired from similar in vitro study. 21 The spirit of Greedy is collecting best components to optimize the composed product. Instead of estimating all the possible potential mutations (which we would need to analyze 20 n peptides), we only estimate 20×n mutations with only 1 mutant position at a time.
Antiplatelet drugs are commonly used in thrombogenic diseases, but acute profound thrombocytopenia is a recognized complication of treatment with antiplatelet drug (eg, GPIIb/IIIa inhibitors), and the cause is not yet fully known. Thrombocytopenia may be associated with a variety of conditions, and life-threatening bleeding is one of its worst side effects. Because GPVI expression deficiency is usually only associated with slightly prolonged bleeding times, it is worth to develop novel GPVI antagonists for thrombogenic diseases. We demonstrated Troα6/Troα10 specifically inhibited collagen-induced platelet aggregation via interacting with platelet GPVI at novel binding epitope. They exhibited a marked antithrombotic effect in vivo with a minimal bleeding side effect. Their action as a specific small-mass GPVI antagonist provides a promising novel molecular skeleton for designing the new class of antithrombotic agents targeting platelet GPVI with limited bleeding side effect. 
